stockrow
Friday 6 November 2026
Export EW’s income statement to Excel — free account
Edwards Lifesciences Corporation
Edwards Lifesciences Corporation’s revenue for fiscal 2025 (year ended December 2025) was $6.1 billion, up 11.5% from fiscal 2024.
- Revenue
- +10.5%
- EPS
- +6.00%
- Free cash flow
- −1.84%
- Total debt
- +0.10%
Quarter to September 2026, against a year earlier
101.94
1.12
+1.11%
Follow EW
Alert me
| Sep '26 From the 10-Q filed 4 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
48.77 | 51.99 | 42.37 | 46.33 |
+8 more quarters Free account |
P/S ratio |
7.45 | 8.01 | 7.36 | 8.22 | |
P/FCF ratio |
35.68 | 37.15 | 43.78 | 38.20 | |
P/Operating CF |
87.23 | 79.98 | 1,058.96 | 110.57 | |
P/B ratio |
4.54 | 4.86 | 4.49 | 4.82 | |
Price to Tangible BV |
6.52 | 7.05 | 6.37 | 6.70 | |
EV/Sales |
7.00 | 7.54 | 6.97 | 7.72 | |
EV/EBITDA |
28.96 | 30.40 | 29.12 | 32.96 | |
EV/Operating CF |
27.20 | 28.53 | 32.32 | 29.35 | |
EV/FCF |
33.49 | 34.97 | 41.44 | 35.88 | |
Quick Ratio |
0.00 | 3.45 | 3.30 | 2.83 | |
Current Ratio |
4.60 | 4.52 | 4.42 | 3.72 | |
Net Debt/EBITDA |
1.74 | (6.57) | (5.93) | (18.72) | |
Debt/Assets |
4.23% | 4.32% | 4.49% | 4.37% | |
Debt/Equity |
0.05 | 0.06 | 0.06 | 0.06 | |
Asset Turnover |
0.49 | 0.48 | 0.48 | 0.45 | |
Operating CF/Net income |
1.85 | 2.69 | 0.12 | 4.94 | |
Capex/Depreciation |
(1.42) | (1.57) | (1.59) | (2.28) | |
Research and Development Expense of Revenue |
16.40% | 16.02% | 15.97% | 17.06% | |
Selling, General and Administrative Expense of Revenue |
32.70% | 32.23% | 31.68% | 38.41% | |
Intangible Assets out of Total Assets |
0.00 | 0.24 | 0.23 | 0.21 | |
Share Based Compensation of Revenue |
2.68% | 2.42% | 2.75% | 2.50% | |
Graham Net Nets |
0.08 | 0.07 | 0.07 | 0.07 | |
Graham Number |
27.52 | 26.99 | 27.54 | 27.05 | |
Earnings Yield |
2.05% | 1.92% | 2.36% | 2.16% | |
Free Cash Flow Yield |
2.80% | 2.69% | 2.28% | 2.62% | |
Revenue per Share |
2.98 | 3.02 | 2.85 | 2.68 | |
Operating CF per Share |
0.99 | 1.13 | 0.08 | 0.77 | |
Capex per Share |
(0.11) | (0.12) | (0.11) | (0.17) | |
Free Cash Flow per Share |
0.88 | 1.01 | (0.04) | 0.60 | |
Cash per Share |
0.00 | 7.38 | 6.34 | 7.23 | |
Shareholders Equity per Share |
19.02 | 18.61 | 17.83 | 17.68 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
19.02 | 18.61 | 17.83 | 17.68 | |
Free Cash Flow |
506.70 | 585.00 | (21.10) | 353.50 | |
Working Capital |
5,670.80 | 5,311.00 | 4,819.70 | 4,925.20 | |
Capital Expenditures |
(63.60) | (66.90) | (64.90) | (97.40) | |
Net Current Asset Value |
4,064.60 | 3,676.70 | 3,235.00 | 3,379.30 | |
EV/EBIT |
32.40 | 33.88 | 32.60 | 37.04 | |
Capex to Sales |
0.04 | 0.04 | 0.04 | 0.06 | |
Price to Operating Income |
34.52 | 35.98 | 34.43 | 39.44 | |
| Other line items | |||||
Average Receivables |
— | 929.15 | 862.45 | 819.75 | |
Average Payables |
182.35 | 186.30 | 176.75 | 212.45 | |
Average Inventory |
1,150.15 | 1,136.45 | 1,116.45 | 1,106.45 | |
Average Assets |
13,708.30 | 13,677.90 | 13,171.75 | 13,376.25 | |
Average Common Equity |
10,583.25 | 10,665.70 | 10,259.55 | 10,200.25 |
Columns are period end dates · fundamentals updated 4 Nov 2026